2025 Oncology Institute
April 19, 2025 | 4:34 PM EST
- Home
- Clinical Resources Search
- PQI in Action: Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma – 2
Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma – 2
Download PQI pdf 1.27MB
Last Updated: March 1, 2023
By: City of Hope, IL | City of Hope, GA | Baptist MD Anderson Cancer Center, FL
About this PQI in Action
In an effort to promote higher quality patient care NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the Enfortumab Vedotin Management for Advanced or Metastatic Urothelial Carcinoma PQI and explores how the medically integrated teams at City of Hope and Baptist MD Anderson Cancer Center incorporate PQIs as part of their daily workflow. This article will discuss how utilizing the Enfortumab Vedotin Management for Advanced or Metastatic Urothelial Carcinoma PQI elevates patient care.
More About This PQI in Action
Find a PQIPQI in Action
PQI in Action: Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma
Last Updated: August 1, 2021
PQI
PQI: Enfortumab Vedotin-ejfv (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma
Last Updated: March 10, 2025
PQI
PQI: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma
Last Updated: March 6, 2025